Efficacy and safety of long-acting nifedipine (GITS) in patients with diabetes and symptomatic stable angina pectoris: insights from the ACTION trial

P.A. Meredith, Henry L. Elliott

Research output: Contribution to journalArticle

Abstract

In the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) trial, the benefits of adding nifedipine GITS to the treatment of patients with stable symptomatic coronary artery disease were particularly apparent in those with concomitant hypertension. This further analysis has assessed whether or not the addition of nifedipine GITS is particularly beneficial in the treatment of patients with the combination of diabetes mellitus and chronic stable angina.
LanguageEnglish
PagesS26-S26
JournalDiabetologia
Volume52
Issue numberSupplement 1
DOIs
Publication statusPublished - Sep 2009

Fingerprint

Stable Angina
Nifedipine
Coronary Disease
Safety
Coronary Artery Disease
Diabetes Mellitus
Hypertension
Therapeutics

Keywords

  • coronary disease
  • long-acting nifedipine
  • diabetes
  • symptomatic stable angina pectoris
  • hypertension
  • diabetes mellitus

Cite this

@article{0d18e6340e034d5ea2a7548796108e90,
title = "Efficacy and safety of long-acting nifedipine (GITS) in patients with diabetes and symptomatic stable angina pectoris: insights from the ACTION trial",
abstract = "In the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) trial, the benefits of adding nifedipine GITS to the treatment of patients with stable symptomatic coronary artery disease were particularly apparent in those with concomitant hypertension. This further analysis has assessed whether or not the addition of nifedipine GITS is particularly beneficial in the treatment of patients with the combination of diabetes mellitus and chronic stable angina.",
keywords = "coronary disease, long-acting nifedipine, diabetes, symptomatic stable angina pectoris, hypertension, diabetes mellitus",
author = "P.A. Meredith and Elliott, {Henry L.}",
year = "2009",
month = "9",
doi = "10.1007/s00125-009-1445-1",
language = "English",
volume = "52",
pages = "S26--S26",
journal = "Diabetologia",
issn = "0012-186X",
number = "Supplement 1",

}

Efficacy and safety of long-acting nifedipine (GITS) in patients with diabetes and symptomatic stable angina pectoris: insights from the ACTION trial. / Meredith, P.A.; Elliott, Henry L.

In: Diabetologia, Vol. 52, No. Supplement 1, 09.2009, p. S26-S26.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and safety of long-acting nifedipine (GITS) in patients with diabetes and symptomatic stable angina pectoris: insights from the ACTION trial

AU - Meredith, P.A.

AU - Elliott, Henry L.

PY - 2009/9

Y1 - 2009/9

N2 - In the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) trial, the benefits of adding nifedipine GITS to the treatment of patients with stable symptomatic coronary artery disease were particularly apparent in those with concomitant hypertension. This further analysis has assessed whether or not the addition of nifedipine GITS is particularly beneficial in the treatment of patients with the combination of diabetes mellitus and chronic stable angina.

AB - In the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) trial, the benefits of adding nifedipine GITS to the treatment of patients with stable symptomatic coronary artery disease were particularly apparent in those with concomitant hypertension. This further analysis has assessed whether or not the addition of nifedipine GITS is particularly beneficial in the treatment of patients with the combination of diabetes mellitus and chronic stable angina.

KW - coronary disease

KW - long-acting nifedipine

KW - diabetes

KW - symptomatic stable angina pectoris

KW - hypertension

KW - diabetes mellitus

UR - http://dx.doi.org/10.1007/s00125-009-1445-1

U2 - 10.1007/s00125-009-1445-1

DO - 10.1007/s00125-009-1445-1

M3 - Article

VL - 52

SP - S26-S26

JO - Diabetologia

T2 - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - Supplement 1

ER -